ADAR1 Capital Management, LLC bought $722k of INM
owner at InMed Pharmaceuticals Inc.. 468,551 shares at an average of $1.54, traded May 19, 2026, filed May 21, 2026.
Score components
- +12Role10% owner
- +21Trade size$722k at market
- +10Relative to holdingsHoldings up 141%
- +8Price context59% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001940272-26-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 19, 2026 | POpen-market purchase Common Sharesindirect: See Footnote | +68,551 | $1.60 | $110k | 400,000 | May 21, 2026 |
| May 19, 2026 | POpen-market purchase Common Sharesindirect: See Footnote | +200,000 | $1.56 | $312k | 600,000 | May 21, 2026 |
| May 19, 2026 | POpen-market purchase Common Sharesindirect: See Footnote | +200,000 | $1.50 | $300k | 800,000 | May 21, 2026 |
Related signals
Other insiders at InMed Pharmaceuticals Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 15, 2026 | INMbuy InMed Pharmaceuticals Inc. | ADAR1 Capital Management, LLC owner | $14k 10,903 shares | +1% | |
| 19Weak | INMbuy InMed Pharmaceuticals Inc. | ADAR1 Capital Management, LLC owner | $57k 42,920 shares | +5% | |
| 20Weak | INMbuy InMed Pharmaceuticals Inc. | ADAR1 Capital Management, LLC owner | $118k 91,101 shares | +11% | |
| 23Weak | InMed Pharmaceuticals Inc. | ADAR1 Capital Management, LLC owner | $1,555 1,000 shares | +0% | |
| 33Weak | InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC owner | $32k 20,546 shares | +3% | |
| 15Weak | INMbuy InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC owner | $10k 6,551 shares | +1% | |
| 49Moderate | InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC owner | $392k 249,227 shares | +51% | |
| 28Weak | INMsell InMed Pharmaceuticals Inc. | Alexandra Diane Janet Mancini Sr VP, Clinical Reg Affairs | $42 240 shares | -100% | |
| 41Moderate | InMed Pharmaceuticals Inc. | Andrew Hull director | $15k 37,500 shares | +4947% | |
| 51Moderate | InMed Pharmaceuticals Inc. | Eric A Adams President & CEO | $15k 41,600 shares | +1763% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.